Skip to content

Study about the efficacy of metformin to immune function in healthy volunteers.

Study about the efficacy of metformin to immune function in healthy volunteers. - Study about the efficacy of metformin to immune function in healthy volunteers.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014337
Enrollment
20
Registered
2014-06-23
Start date
2014-06-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers

Interventions

Administering metformin of 500 mg after each meal everyday for two weeks.

Sponsors

Okayama University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Subjects who received a full explanation of the study and gave a written informed consent. 2. Subjects who weigh 50 to 80 kg and whose BMI is 18.5 or higher and less than 25. 3. Subjects who can complain abnormal and subjective symptoms if they suffer from them during the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who have symptoms which are judged to require follow-up or treatment. 2. Subjects who have previous medical history of hepatic disease, renal disease, cardiovascular disease, endocrine disease, gastrointestinal disease, respiratory disease, blood disorders and malignancy. 3. Subjects who have previous medical history of lactic acidosis. 4. Subjects who are allergic to medicines. 5. Subjects who need to take other medicines from 7 days before the study to the end of it. 6. Subjects who have drinking habit. 7. Subjects who drink caffeine-containing beverage in daily average of 1.8 L or more (coffee, tea, green tea, cola, health drink, etc.) 8. Subjects who smoke 2 packs or more in daily average. 9. Subjects who have been enrolled in the other clinical trials within last 4 months before the administration of metformin and administered any investigational new drugs. 10. Subjects who have made a blood donation prior to the administration of metformin. 11. Subjects who have been shown any problems at health examination. 12. Pregnant wouman 13. Other subjects who are judged to be ineligible in this trial by the investigator.

Design outcomes

Primary

MeasureTime frame
Ability to produce cytokines (IL-2, TNF alpha, IFN gamma) and differentiation (memory, helper etc.) in peripheral blood T cells.

Countries

Japan

Contacts

Public ContactMototsugu Watanabe

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of General Thoracic Surgery and Breast and Endocrinological Surgery

mowatanabe@s.okayama-u.ac.jp086-235-7265

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026